As with systemic lymphoma, the classification of PCL is constantly being modified by advances in molecular pathology. These advances allow more accurate classification and diagnosis, particularly in entities with overlapping morphology but very different clinical courses. The latest (2016) revision of the WHO classification of lymphoid neoplasms (Swerdlow S et al. The 2016 revision of the World Health Organisation classification of lymphoid neoplasms. Blood. 2016; 127(20) :2375-2390), includes some changes to pre-existing PCL entities and also lists a new provisional entity (Table 2 overleaf ). This table does not include extracutaneous lymphomas that frequently secondarily involve the skin.
Of the PCLs, approximately 65% are cutaneous T-cell lymphomas (CTCLs), 25% are cutaneous B-cell lymphomas and 10% are uncommon immature haematopoietic forms. Primary CTCLs can be divided into those with indolent or aggressive behaviour (Table 1 below). The indolent lymphomas often remain localised to the skin for many years but systemic spread may eventually occur with some. The aggressive lymphomas usually present with extensive skin involvement at the time of diagnosis. Systemic symptoms and rapid spread to other organs are also common in the aggressive lymphomas, with the exception of Sézary syndrome. In these cases, distinguishing between a PCL and secondary skin involvement is less important than for the indolent lymphomas.
>>> Continued Overleaf

PRIMARY CUTANEOUS LYMPHOMA
Key points
These are lymphomas that occur in the skin, with no evidence of systemic disease at diagnosis. Accurate diagnosis is essential as the prognosis can change from excellent to rapidly fatal, depending on the type of lymphoma. Expert review of biopsies is recommended.
It is essential to distinguish between primary cutaneous lymphoma and secondary cutaneous involvement by systemic lymphoma as the treatment and prognosis can be stark.
Referral for specialist review is required. 
